| Symbol | ADIL |
|---|---|
| Name | ADIAL PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA 22901 |
| Telephone | 434-422-9800 |
| Fax | — |
| — | |
| Website | https://www.adialpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001513525 |
| Description | Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. Additional info from NASDAQ: |
Coastlands Capital LP 🟢 acquired 3.2K shares of ADIAL PHARMACEUTICALS, INC. (ADIL) at $2.75 Transaction Date: Jul 14, 2026 | Filing ID: 084300
Read moreCoastlands Capital LP 🟢 acquired 25.0K shares of ADIAL PHARMACEUTICALS, INC. (ADIL) at $2.60 Transaction Date: Jun 29, 2026 | Filing ID: 079686
Read moreNew Form 3 - ADIAL PHARMACEUTICALS, INC. <b>Filed:</b> 2026-06-29 <b>AccNo:</b> 0001104659-26-078710 <b>Size:</b> 15 KB
Read moreNew Form SCHEDULE 13G - ADIAL PHARMACEUTICALS, INC. <b>Filed:</b> 2026-06-24 <b>AccNo:</b> 0001104659-26-077127 <b>Size:</b> 27 KB
Read moreAdial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing
Read moreDirector Davidson Matt 🟢 acquired 531.8K shares (1 derivative) of ADIAL PHARMACEUTICALS, INC. (ADIL) at $2.89 Transaction Date: Jun 11, 2026 | Filing ID: 069037
Read moreDirector Young Wendy B. 🟢 acquired 36.4K shares (1 derivative) of ADIAL PHARMACEUTICALS, INC. (ADIL) at $0.00 Transaction Date: Jun 12, 2026 | Filing ID: 069021
Read moreNew Form 3 - ADIAL PHARMACEUTICALS, INC. <b>Filed:</b> 2026-06-16 <b>AccNo:</b> 0001213900-26-069035 <b>Size:</b> 3 KB
Read moreNew Form 3 - ADIAL PHARMACEUTICALS, INC. <b>Filed:</b> 2026-06-16 <b>AccNo:</b> 0001213900-26-069015 <b>Size:</b> 11 KB
Read more(85% Positive) ADIAL PHARMACEUTICALS, INC. (ADIL) Announces Business Combination
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT04101227 | Study to Evaluate AD04 in Adults With Alcohol Use Disorder (AUD) and Selected S… | Phase3 | Alcohol Use Disorder | Completed | 2020-02-01 | 2022-03-18 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Brief Psychological Counseling | Other | Phase PHASE3 | Alcohol Use Disorder | COMPLETED | NCT04101227 |
| Companion Diagnostic for Genetic Testing | Other | Phase PHASE3 | Alcohol Use Disorder | COMPLETED | NCT04101227 |
| Matching placebo | Other | Phase PHASE3 | Alcohol Use Disorder | COMPLETED | NCT04101227 |
| AD04 (ondansetron) | Other | Phase PHASE3 | Alcohol Use Disorder | COMPLETED | NCT04101227 |
| ADS-8902 | DRUG | Phase PHASE2 | Influenza | COMPLETED | NCT00979251 |
| Oseltamivir Phosphate | DRUG | Phase PHASE2 | Influenza | COMPLETED | NCT00979251 |
| ADS-5102 (extended release amantadine HCl) | DRUG | Phase PHASE2 | Dyskinesia | COMPLETED | NCT01397422 |
| ADS-5102 | DRUG | Phase PHASE2 | Walking Impairment | COMPLETED | NCT02471222 |
| ADS-5102, 274 mg | DRUG | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT03567057 |
| 320mg Amantadine HCl ER tablets | DRUG | Phase PHASE3 | Parkinson's Disease | TERMINATED | NCT02153645 |
| Placebo tablets | DRUG | Phase PHASE3 | Parkinson's Disease | TERMINATED | NCT02153645 |
| 240mg Amantadine HCl ER tablets | DRUG | Phase PHASE3 | Parkinson's Disease | TERMINATED | NCT02153645 |
| Placebo | OTHER | Phase PHASE2 | Walking Impairment | COMPLETED | NCT02471222 |
| amantadine HCl ER | DRUG | Phase PHASE3 | Parkinson's Disease | TERMINATED | NCT02153632 |
| GOCOVRI | DRUG | Phase PHASE4 | Parkinson Disease | COMPLETED | NCT04387773 |